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Corrigendum to ‘‘Rationale and design of the NAGOYA HEART Study:
Comparison between valsartan and amlodipine regarding morbidity
and mortality in patients with hypertension and glucose intolerance’’
[J. Cardiol. 56 (2010) 111–117]
Kunihiro Matsushita (MD, PhD), Takashi Muramatsu (MD), Takahisa Kondo (MD, PhD),
Kengo Maeda (MD, PhD), Satoshi Shintani (MD, PhD), Toyoaki Murohara (MD, PhD)*, on
behalf of the NAGOYA HEART Study Group
Department of Cardiology, Nagoya University Graduate School of Medicine, 65 Tsurumai, Showa-ku, Nagoya 466-8550, Japan
The authors of the manuscript would like to correct afﬁliation of Mr. Nobuo Shirahashi, who was mentioned in the Appendix section of
this article. The correct afﬁliation of Mr. Shirahashi was Novartis Pharma KK and Department of Preventive Medicine and Environmental
Health, Osaka City University Medical School, Osaka, Japan.
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